Overactive Bladder (OAB)

Overactive Bladder in Men Linked to Excessive Visceral Fat

Publish Date May 15, 2022

In a Japanese study, men with vs without OAB had a significantly higher visceral fat area and visceral fat volume.

COVID-19 Infection Ups Risk for New or Worsening OAB Symptoms

Publish Date May 15, 2022

COVID-19-associated cystitis appears to be a common problem among infected individuals.

Morbid Obesity Ups Odds of Multiple Urologic Conditions

Publish Date May 14, 2022

Efforts to reduce obesity may cut the prevalence of these urological conditions.

Donepezil Tied to Risk for Overactive Bladder

Publish Date January 25, 2022

Risk for overactive bladder varies across individual cholinesterase inhibitor drugs

Overactive Bladder, Urinary Incontinence Common in Middle-Aged Women

Publish Date January 13, 2022

Age and menopause status tied to increased urinary symptoms in women

Botulinum Toxin’s Efficacy for Post-Prostatectomy OAB Varies by Subtype

Publish Date October 20, 2021

Long-term post-prostatectomy urinary incontinence affects 3% to 10% of patients.

OAB Symptoms Increase With Longer BCG Therapy for NMIBC

Publish Date October 19, 2021

Intravesical BCG therapy is effective in treating NMIBC, but it comes with side effects such as overactive bladder.

Sacral Neuromodulation for Overactive Bladder Shows Real-World Efficacy

Publish Date September 20, 2021

Over 10 months, complete continence was achieved by approximately half of implanted patients.

Telemedicine Appears Effective for Managing Overactive Bladder

Publish Date September 13, 2021

A small randomized trial finds no worse satisfaction with telemedicine vs in-person visits among patients with OAB.

PTNS Compliance Is Low Among Patients With OAB

Publish Date September 13, 2021

In a single-center study, the median duration of percutaneous tibial nerve stimulation therapy was 147 days.